Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 11:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 9,123 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Recurrent Neoplasm Clear all

Conditions: Brain and Central Nervous System Tumors
Interventions: irinotecan hydrochloride; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Boston, Massachusetts + 6 more

Conditions: Prostate Cancer
Interventions: MUC-2-Globo H-KLH conjugate vaccine, QS21; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Recurrent Non-small Cell Lung Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer
Interventions: stereotactic radiosurgery, therapeutic conventional surgery, laboratory biomarker analysis, quality-of-life assessment; Radiation · Procedure · Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer
Interventions: fulvestrant; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 24
States / cities: Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 21 more

Conditions: Estrogen Receptor Positive, HER2 Positive Breast Carcinoma, HER2/Neu Negative, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Fulvestrant, Laboratory Biomarker Analysis, Lapatinib Ditosylate, Placebo Administration; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 368
States / cities: Little Rock, Arkansas • Arroyo Grande, California • Burbank, California + 259 more

Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
Interventions: Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 6
States / cities: Beverly Hills, California • Duarte, California • Los Angeles, California + 3 more

Conditions: Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
Interventions: Bendamustine Hydrochloride, Brentuximab Vedotin; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Hodgkin's Disease
Interventions: MDX-060; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 17
States / cities: Duarte, California • Fresno, California • La Jolla, California + 14 more

Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions: bortezomib; Drug
Lead sponsor: University Health Network, Toronto; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 11
States / cities: Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 8 more

Conditions: High Grade Glioma
Interventions: SONALA-001(ALA) and MR-Guided Focused Ultrasound device (MRgFUS), MR-Guided Focused Ultrasound device (MRgFUS); Combination Product · Device
Lead sponsor: Nader Sanai; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Recurrent Abdominal Pain
Interventions: chamomile tea, Relaxation/Guided Imagery; Drug · Procedure
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 0 Years to 20 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome
Interventions: Azacitidine, Venetoclax; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Squamous Cell Carcinoma of Head and Neck
Interventions: CMP-001, Pembrolizumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 19
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 15 more

Conditions: Malignant Brain Neoplasm, Metastatic Malignant Neoplasm in the Brain, Recurrent Malignant Brain Neoplasm
Interventions: Dexamethasone; Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Duarte, California

Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Actinium Ac 225-DOTA-Daratumumab, Daratumumab, Indium In 111-DOTA-Daratumumab; Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Male Breast Carcinoma, Prostate Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Prostate Carcinoma, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Prostate Cancer
Interventions: Stereotactic Body Radiation Therapy (SBRT); Radiation
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 74
States / cities: Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 66 more

Conditions: Prostate Cancer
Interventions: doxorubicin hydrochloride, estramustine phosphate sodium, drug resistance inhibition treatment; Drug · Procedure
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2013
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Behavior, Cancer
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Colorectal Cancer
Interventions: FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin; Drug
Lead sponsor: Prologue Research International; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 74
States / cities: Tucson, Arizona • Pine Bluff, Arkansas • Covina, California + 66 more

Conditions: Ovarian Cancer
Interventions: Olaparib; Drug
Lead sponsor: Sarah E Taylor; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Multiple Myeloma
Interventions: SGN-40 (anti-huCD40 mAb); Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 5
States / cities: West Hollywood, California • Denver, Colorado • Boston, Massachusetts + 2 more

Conditions: Neoplasm
Interventions: SGT-53, Topotecan, Cyclophosphamide; Genetic · Drug
Lead sponsor: SynerGene Therapeutics, Inc.; Industry
Eligibility: 12 Months to 21 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Interventions: AMG 386, AMG 386 Placebo, Paclitaxel; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 919 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 35
States / cities: Phoenix, Arizona • Los Angeles, California • San Diego, California + 26 more

Conditions: Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: ixazomib, mitoxantrone hydrochloride, etoposide, cytarabine; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Cleveland, Ohio

Search by objective public record fields.

Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma

Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer

Stereotactic Radiosurgery Followed by Wedge Resection in Treating Patients With Early Stage Peripheral Non-small Cell Lung Cancer

ICI 182780 in Treating Women With Metastatic Breast Cancer

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease

Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter

Study of Sonodynamic Therapy in Participants With Recurrent High-Grade Glioma

Treatment of Functional Abdominal Pain in Children: Evaluation of Relaxation/Guided Imagery and Chamomile Tea as Therapeutic Modalities

Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome

CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Low Dose Versus Standard Dose Dexamethasone for Reduction of Swelling in Patients with Primary or Metastatic Brain Tumors

Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma

Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer

Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

Communicating a Cancer Diagnosis-Current Methods and Their Effects

Fluorouracil and Leucovorin With or Without Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer

Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer

Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma

A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors

TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia